Merck KGaA Raises 2026 Outlook as Third-Quarter Sales Rise 5.8%

Merck KGaA raised its full-year 2026 outlook Thursday after third-quarter net sales climbed 5.8% year over year to €5.627 billion, reflecting stronger underlying performance and more favorable foreign exchange effects.

Earnings per share pre was €2.32, unchanged from the year-earlier quarter.

Merck now expects full-year net sales of €21.5 billion to €21.9 billion, up from its previous forecast of €21.0 billion to €21.8 billion. Its EBITDA pre outlook increased to €6.2 billion to €6.4 billion, compared with the earlier range of €5.9 billion to €6.3 billion.

The company also raised its EPS pre forecast to €8.30 to €8.70. Its prior range was €7.90 to €8.60.

The revised outlook includes Bio-Techne as a December portfolio effect and assumes no U.S. Mavenclad sales from November.